In recent years, liver transplant eligibility criteria for HCC have evolved beyond the traditional Milan criteria, incorporating dynamic predictors, such as tumor biology, response to treatment, and non-invasive biomarkers, like AFP levels [31]. This evidence concerns the gene AFP and neoplasm.